Zimmer Biomet (NYSE:ZBH – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Argus in a note issued to investors on Thursday, Benzinga reports. They presently have a $125.00 price objective on the medical equipment provider’s stock. Argus‘s price objective would indicate a potential upside of 26.85% from the stock’s previous close.
A number of other brokerages have also issued reports on ZBH. Wall Street Zen lowered shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. BMO Capital Markets reissued a “market perform” rating on shares of Zimmer Biomet in a research note on Monday, September 28th. Stifel Nicolaus lifted their target price on shares of Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Canaccord Genuity Group lifted their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research note on Monday, August 10th. Finally, Royal Bank Of Canada lifted their price objective on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Seven research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $104.47.
Zimmer Biomet Trading Up 3.9%
Zimmer Biomet stock traded up $3.68 during midday trading on Thursday, reaching $98.54. The stock had a trading volume of 606,885 shares, compared to its average volume of 2,224,000. The firm’s fifty day simple moving average is $95.18 and its two-hundred day simple moving average is $91.41. Zimmer Biomet has a twelve month low of $79.12 and a twelve month high of $104.15. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The firm has a market cap of $18.80 billion, a price-to-earnings ratio of 23.91, a PEG ratio of 1.81 and a beta of 0.49.
Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company’s revenue was up 4.8% on a year-over-year basis. During the same quarter last year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities analysts anticipate that Zimmer Biomet will post 8.54 EPS for the current fiscal year.
Insider Buying and Selling at Zimmer Biomet
In other news, insider Chad F. Phipps sold 3,000 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. Company insiders own 1.28% of the company’s stock.
Institutional Trading of Zimmer Biomet
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tacita Capital Inc bought a new stake in Zimmer Biomet in the second quarter valued at about $26,000. Ancora Advisors LLC bought a new stake in Zimmer Biomet in the second quarter valued at about $29,000. Elevation Wealth Partners LLC increased its stake in Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 229 shares during the period. Cassaday & Co Wealth Management LLC bought a new stake in Zimmer Biomet in the first quarter valued at about $44,000. Finally, Parvin Asset Management LLC bought a new stake in Zimmer Biomet in the second quarter valued at about $47,000. Institutional investors own 88.89% of the company’s stock.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.
The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.
Featured Articles
- Five stocks we like better than Zimmer Biomet
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
